UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 8, 2018

SCYNEXIS, Inc.
(Exact name of registrant as specified in its charter)

Delaware	**001-36365**	**56-2181648**
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

101 Hudson Street, Suite 3610
Jersey City, New Jersey 07302-6548
(Address of principal executive offices, including zip code)

(201)-884-5485
(Registrant's telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 7.01 Regulation FD Disclosure.

SCYNEXIS, Inc. (the "Company") will be attending investor conferences and conducting investor meetings during the first quarter of 2018. In connection with these meetings, the Company intends to discuss the slide presentation attached as Exhibit 99.1 (the "Corporate Presentation") to this current report on Form 8-K (the "Current Report"). The Company's current development strategy and outlook for its lead product candidate, SCY-078, is described in the Corporate Presentation.

In accordance with General Instruction B.2. of Form 8-K, the information contained in Item 7.01 in this report (including the Corporate Presentation) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall the Corporate Presentation be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended. This Current Report will not be deemed a determination or an admission as to the materiality of any information in the Corporate Presentation that is required to be disclosed by Regulation FD.

Item 9.01 Financial Statements and Exhibits.

Exhibit Index

Exhibit No.	Description
99.1	Corporate Presentation

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SCYNEXIS, Inc.

Dated: January 8, 2018

By: /s/ Eric Francois
Eric Francois

Chief Financial Officer

SCYNEXIS®

A New Path for Antifungal Treatments

SCY-078 – First Representative of a Novel Oral/IV Triterpenoid Antifungal Family

CORPORATE PRESENTATION | January 2018

scynexis.com

NASDAQ: SCYX

Forward-Looking Statements

Certain statements regarding SCYNEXIS, Inc. (the "Company") made in this presentation constitute forward-looking statements, including, but not limited to, statements regarding our business strategies and goals, plans and prospects, market size, adoption rate, potential revenue, clinical validity and utility, growth opportunities, future products and product pipeline. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our expectations. These risks and uncertainties include, but are not limited, to: risks inherent in SCYNEXIS' ability to successfully develop SCY-078, including SCYNEXIS' ability to resolve the FDA's concerns regarding the IV formulation of SCY-078 on a timely basis, if at all, and obtain FDA's approval for SCY-078; the expected costs of studies and when they might begin or be concluded; and SCYNEXIS' reliance on third parties to conduct SCYNEXIS' clinical studies. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "could," "should," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent reports filed with the Securities and Exchange Commission ("SEC") including under the caption "Risks Factors" in the Company's annual report on Form 10-K, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. The Company undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this presentation, or to reflect actual outcomes.

SCYX: Investment Opportunity



Foundation: Experienced Management

LEADERSHIP

Positive track record in drug development & antifungal expertise

CEO: Marco Taglietti, M.D.
Schering-Plough, Stiefel, Forest Labs

CMO: David Angulo, M.D.
Schering-Plough, Stiefel, Brickell Biotech

CFO: Eric Francois
Cowen, Lazard, Topi

General Counsel: Scott Sukenick
Cooley

BOARD OF DIRECTORS

Diverse backgrounds & operating experience

Guy Macdonald, Chairman (Tetraphase, Merck)

Steven Gilman, Ph.D. (Contrafect, Cubist)

Ann Hanham, Ph.D. (BAR Capital, Burrill)

David Hastings (Unilife, Incyte)

Patrick Machado (Medivation)

Marion McCourt (Axovant, Medivation, Amgen)

SCYNEXIS

Foundation: Favorable Technicals

NASDAQ: SCYX

- Market value (as of 1/4/18): $2.42 mm
- Total cash (as of 9/30/17): $48mm
- $15mm debt agreement (Solar Capital)
- 3-month trading volume (as of 1/4/18): 200K

Q3'17 TOP SHAREHOLDERS

Firm Name	% O/S	Q3'17 Pos.
Federated	15.0	4,291,800
The Vanguard Group	2.9	832,987
Rock Springs Capital Management	2.7	760,000
Dafna Capital Management	1.8	506,900
National Asset Management	1.0	279,255
Iguana Healthcare Management	0.9	250,000
Highland Capital Healthcare Advisors	0.9	246,960
FT Options	0.8	241,236
CAPERS	0.7	200,000
GSA Capital Partners	0.6	176,700

RESEARCH COVERAGE

Firm	Analyst	Rating	PT
Aegis Capital	Robert LeBoyer	Buy	$5.00
Brookline	Kumar Raja	Buy	$8.00
Canaccord Genuity	Arlinda Lee	Buy	$11.00
Guggenheim	Adnan Butt	Buy	$6.00
HC Wainwright	*Transition*	---	---
National Securities	Jonathan Aschoff	Buy	$14.00
Needham	Alan Carr	Hold	---
Roth Capital	*Transition*	---	---
WBB Securities	Stephen Brozak	Buy	$8.00

Excludes Insiders and Index Funds.

SCYNEXIS

SCY-078: A Novel Triterpenoid Antifungal

Broad Spectrum (MDR Strains)

Flexible Dosing IV / Oral

Fungicidal vs. *Candida*



Safe Well-Tolerated

Validated MOA

Low Risk of DDIs

High Tissue Penetration

Worldwide Rights and Long Exclusivity (IP up to 2035)

QIDP, Fast Track and Orphan Drug status for Invasive Candidiasis and Aspergillosis

SCY-078 is an investigational drug. Items listed on this slide illustrate SCY-078 target attributes.

SCY-078: Strong Scientific Evidence



SCY-078 is an investigational drug.

SCYNEXIS

SCY-078: Validated MoA



- Minimal Limited off-target effects
- High distribution to key tissues
- Oral bioavailability ~ 36%
- Mean half-life of ~20 hours

SCY-078 is an investigational drug. Items listed on this slide illustrate SCY-078 target attributes.

SCYNEXIS®

SCY-078: Effect on *Candida* spp. Cell Wall

Potent activity of SCY-078 vs. MDR C. *auris* in 2 *in vitro* studies

C. *auris* before SCY-078



C. *auris* after SCY-078



Larkin E., et al. The Emerging Pathogen *Candida auris*: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation. Antimicrob Agents Chemother. 2017 May; 61(5).

SCY-078 is an investigational drug.

SCYNEXIS®

SCY-078: Key Attributes vs. SoC Agents

	SCY-078	Echinocandin	Azole	Ampho B
Market Introduction Timelines	TBD	2000s	1980s	1960s
Spectrum of Antifungal Activity				
Active vs. *Candida albicans*	✓	✓	✓	✓
Active vs. *Candida glabrata*	✓	✓		✓
Active vs. *Candida auris*	✓	✓		
Active vs. Azole-Resistant	✓	✓		✓
Active vs. Echinocandin-Resistant*	✓			✓
Fungicidal vs. *Candida* spp.	✓	✓		✓
Active vs. *Aspergillus* spp.	✓	✓	✓	✓
Safety Profile**	✓	✓		
IV and Oral Formulations Available	✓		✓	
Worldwide Sales[a]		~$1B	~$1.5B	~$600mm

* Active against most echinocandin-resistant *Candida* isolates | **Lack of renal, hepatic, CNS toxicities and low risk of drug-drug interactions.

SCY-078 is an investigational drug – items listed on this chart illustrate SCY-078 target attributes.

a. IMS Data 2013

SCYNEXIS®

SCY-078: Platform of Differentiated Indications



Additional indications under consideration: Chronic Fungal Infections, Prophylaxis

SCY-078 is an investigational drug. *Start of Phase 2b study post completion of Phase 1 with IV formulation pending resolution of IV clinical hold.

SCYNEXIS®

Opportunity in Invasive Candidiasis

Growing Antifungal Resistance
Azole resistance ~10-15%
Echinocandin resistance ~3-5%
WW appearance of MDR *C. auris*

SCY-078

Broad Spectrum Of Activity
vs. Azole-resistant strains
vs. Majority of echinocandin-resistant strains
vs. MDR *C. auris*

Unsatisfactory Clinical Outcomes
Mortality still up to 30%

Fungicidal vs. *Candida*
High volume of distribution and excellent penetration into relevant tissues

Limited Therapeutic Options
Glucan Synthase inhibitors are best treatment option but only available IV

Validated MOA (Glucan Synthase Inhibitor)
Flexible Dosing with IV/Oral
Allowing long treatment durations

SCY-078 is an investigational drug.

Invasive Candidiasis Opportunity: US

SCY-078 provides an alternative to current echinocandin use in empiric and confirmed cases of IC, and a significant improvement vs. fluconazole for step-down therapy



- Echinocandin is limited (only-IV available)
  - ✓ ~1.8MM DOT in US
  - ✓ ~1B in sales worldwide

Product Opportunity

ROW opportunity expected to be similar to US Market

Targets:

- Echinocandin-resistant
- Echinocandin intolerant
- Azole-resistant
- Step down

* Preliminary assessment (to be further validated) SCY-078 is an investigational drug.
Source: IMS MIDAS 2015 (SU), CDC

SCYNEXIS®

Invasive Candidiasis Development Plan

1 P1 IV	1 P2b IV-Oral	1 P3 IV-Oral
Planned for Q3 2018	Planned initiation Q4 2018 2 doses of SCY-078 (IV and oral) vs. SoC	1 P3 study required 1 dose of SCY-078 (IV and oral) vs. SoC

ONGOING: Open-label Phase 3 Studies (**FURI** and **CARES**) vs. historical controls

- **FURI study**: Severe or invasive refractory *Candida* infections
- **CARES study**: Infections caused by *Candida auris*, a pathogen that is often multidrug-resistant and associated with high mortality. Study designed to provide rapid access to oral SCY-078 for C. *auris* patients
- **Both studies** have potential eligibility to Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD)

SCY-078 is an investigational drug.

Invasive Candidiasis Data To-Date

Phase 2a - Objectives & Design

- Identify an oral dose of SCY-078 that would achieve the target exposure in patients with invasive candidiasis
- Collect safety and tolerability data of oral SCY-078 in the invasive candidiasis population
- Provide an initial efficacy evaluation of SCY-078 in invasive candidiasis
- Oral SCY-078 after IV echinocandin*
  - 2 dose regimens of oral SCY-078 vs. SoC
- 27 patients with IC enrolled
- Endpoints:
  - Primary: Safety, Tolerability and PK
  - Exploratory: Efficacy at end of therapy and relapse rates

Phase 2a - Results

- Oral dose of 750mg QD achieved target exposure in patients with invasive candidiasis
- Safe and well tolerated. Most common AEs were mild or moderate GI-related events in:
  - 29% of 750mg SCY-078 patients
  - 43% of fluconazole patients

	SCY-078 750mg (N=7)	FLU 400mg (N=7)
Favorable Response	6 (86%)	5 (71%)
"Failures"**	1 administrative-related	2 infection-related
Relapses during Follow-Up Period	0	0

SCY-078 is an investigational drug.

* Resolution of signs and symptoms and microbiological eradication at end of treatment. Based on Intent-to-Treat (ITT) population.
** SCY-078: 1 patient withdrew consent (unrelated to study drug) | Fluconazole: 1 abdominal sepsis, 1 Fungemia.

SCYNEXIS®

Invasive Candidiasis Upcoming Studies

- Main design of both Phase 2 and Phase 3 trials
  - Double-blind, randomized, multi-national, active comparator, non-inferiority (Phase 3) vs. Standard of Care
  - ~ 60 anticipated patients for Phase 2b
  - ~ 200 anticipated patients for Phase 3
- Main endpoints
  - Primary: Global response at end of antifungal therapy
  - Secondary: All cause mortality days 14 and 56 and global response 2 weeks after end of therapy



SCY-078 is an investigational drug.

SCYNEXIS

Opportunity in Vulvovaginal Candidiasis

A significant problem

75% of women will have at least 1 episode
40%–45% will have 2 or more
Candida glabrata infections are increasing

Recurrent ~10% of all VVC

30%-50% of women will recur once maintenance is discontinued

Limited Therapeutic Options

Only Fluconazole available as oral therapy for acute
No treatment approved for recurrent

SCY-078

Broad spectrum of anti-*Candida* activity
(including *albicans* and non-*albicans* spp.)
Active against azole resistant strains

Fungicidal vs. *Candida*
Excellent penetration into vaginal tissue
Potent antifungal activity in vaginal pH

Novel Oral Glucan Synthase Inhibitor
Safe and well tolerated
High clinical cure and low recurrence in P2a

SCY-078 is an investigational drug.

Vulvovaginal Candidiasis Opportunity: US

SCY-078 provides a significant benefits for women with recurrent VVC and an additional option for women with severe/complicated cases



SCY-078 is an investigational drug
Source: NIH and CDC VVC statistics.

* Preliminary assessment (to be further validated)

SCYNEXIS

Vulvovaginal Candidiasis Data To-Date

Phase 2a - Efficacy

- Proof of concept: show anti-*Candida* clinical activity in VVC model
  - Active reference arm performed as expected, validating the study
- Evidence of efficacy and lower relapse rates in VVC

Phase 2a – Safety/Tolerability

- Positive systemic safety
- No serious AEs and discontinuations
- Higher frequency of GI mild/moderate, short-duration AEs vs. fluconazole





SCY-078 is an investigational drug.

Results from per protocol (PP) population (70) consistent with Intent-to-Treat (ITT) population (96). * Based on PP population (70)
Results from 2 SCY-078 arms performed consistently → results presented on a combined basis.

SCYNEXIS

Vulvovaginal Candidiasis Development Plan

ONGOING: Phase 2 dose-finding study (DOVE) vs. oral fluconazole
Top-line results expected mid-2018

Endpoints: % of patients (180 patients with moderate to severe V.V.C.) with clinical cure* and mycological eradication** at day 10 and day 25



Phase 3 Program

- Two Phase 3 studies in acute VVC
- A Phase 2/3 study in recurrent VVC
- Start of the Phase 3 program in Q4 2018

SCY-078 is an investigational drug. * complete resolution of signs and symptoms | ** negative fungal culture.

Opportunity in Invasive Aspergillosis Combo

Emergence of *A. fumigatus* Resistance

Unsatisfactory Clinical Outcomes
Mortality still up to 50%
Long treatment durations

Need for New Treatment Options
Triazoles safety profiles vary
Risk of DDIs

SCY-078

Oral Formulation
High penetration to the lungs

Combination therapy may provide an improvement in survival
Pre-clinical synergistic activity with azoles

Novel Oral Glucan Synthase Inhibitor
Safe and well tolerated
Low risk of DDIs

SCY-078 is an investigational drug.

Invasive Aspergillosis Data To-Date

- Neutropenic rabbit model of pulmonary aspergillosis evaluating SCY-078 alone and in combination with Isavuconazole (n=6 / group)
- Doses: (IV) SCY-078 2.5, 7.5 mg/kg; (PO) Isavuconazole 40 mg/kg for 12 days
- Study endpoints included survival, lung fungal burden, lung weight and lung infarct score
- **Preliminary results**: noticeable survival improvement with combination therap





SCY-078 is an investigational drug.

SCYNEXIS

Invasive Aspergillosis Development Plan

1 P2a Oral IA Combo	1 P3 IV-Oral IA Combo
Planned for Q3 2018 SCY-078+SoC vs. SoC alone	1 P3 study required SCY-078+SoC vs. SoC alone

Global, open-label Phase 3 Study (**FURI**) vs. historical controls

- **FURI study**: Severe or invasive refractory *Aspergillus* infections
- Currently for *Candida* infections only. Protocol to be amended in H2 2018 to add *Aspergillus* infections
- Potential eligibility to Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD)

SCY-078 is an investigational drug.

SCYX: Discovery Platform/Pipeline

- SCY-078 analogues
  - Benefit:
    - Build upon proof-of-concept already established with SCY-078
  - Effort completed to date:
    - **28** structural analogues screened against a panel of yeasts, molds and dermatophytes
    - **3** identified as compounds of interest
- Further evaluation and characterization planned for 2018

SCY-078 is an investigational drug.

Our Vision for 2018



SCY-078 is an investigational drug.

SCYNEXIS

SCYX: Conclusion

- Broad Spectrum, including MDR Strains
- Validated MOA
- Fungicidal vs. *Candida*
- High Tissue Penetration
- IV and Oral

- Worldwide Rights & Long Exclusivity (IP up to 2035)
- QIDP, Fast Track & Orphan Drug Status for Invasive Candidiasis and Aspergillosis



Antifungal clinical development experience

Adequate cash balance, liquidity, research coverage and holders

SCYNEXIS®

A New Path for Antifungal Treatments

Thank You